NCT06883019招募中不适用
A Real World Study of Lecanemab Treatment in Participants with Early Onset Familial Alzheimer's Disease
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 114
- 试验地点
- 15
- 主要终点
- Chang of CDR-SB score
研究概览
简要总结
The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD. Participants will receive Lecanemab at a dosage of 10 mg/kg every two weeks for a total of 18 months and will undergo cognitive assessments, PET and MRI scans, blood/fluid tests and whole genome sequencing. The study will explore the effects of genetic and hereditary factors on the efficacy of Lecanemab treatment in early-onset familial AD patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age at onset ≤ 65 years, with a minimum age of 18 years; no restriction on gender.
- •Diagnosis of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI): Must meet the clinical diagnostic criteria for AD-related MCI and mild AD as defined by the National Institute on Aging and the Alzheimer's Association (NIA-AA) (2011); confirmed Aβ positivity through Aβ-PET/CT, Aβ-PET/MRI, or cerebrospinal fluid testing.
- •MMSE ≥ 21 or MoCA ≥ 17 or CDR = 0.5
- •No significant signs found in the neurological examination
- •Participants must be capable of completing cognitive assessments and other tests.
- •Informed consent must be obtained from the participants and their legal guardians, with a dated signature, prior to any operations or tests related to the protocol, committing to comply with the research procedures and cooperate throughout the study process.
排除标准
- •Cognitive decline caused by other reasons: cerebrovascular disease, central nervous system infections, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, Lewy body dementia, traumatic dementia, other physical and chemical factors (drugs, alcohol, CO, etc.), significant systemic diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial space-occupying lesions (subdural hematoma, brain tumor), endocrine system disorders (thyroid disease, parathyroid disease), and dementia caused by vitamin deficiencies or any other reasons.
- •Patients with other unstable diseases, or those who have had a stroke or transient ischemic attack, bleeding disorders, or seizures within the previous 12 months.
- •Patients with psychiatric disorders who meet DSM-IV criteria for schizophrenia or other mental illnesses, bipolar disorder, major depression, or delirium.
- •Patients with unstable or severe heart, lung, liver, kidney, hematological diseases; those with known malignancies or other serious prognoses.
- •Exclusion of cerebral amyloid angiopathy-related inflammation/β-amyloid-related cerebral vasculitis (CAAri/ABRA).
- •Presence of uncorrectable visual or auditory impairments that prevent completion of relevant assessments or scales.
- •Patients who cannot undergo MRI due to claustrophobia, pacemakers, defibrillators, or metal implants.
- •MRI findings showing more than four microhemorrhages (diameter < 10 mm), evidence of surface iron deposition, vascular edema, diffuse white matter disease, multiple lacunar strokes, or any strokes involving major vascular regions. Presence of evidence of cerebral contusions, brain softening, cerebral aneurysms, or other vascular malformations, central nervous system (CNS) infections, as well as brain tumors other than meningiomas or arachnoid cysts.
- •Patients taking warfarin, vitamin K antagonists, or direct oral anticoagulants (dabigatran, rivaroxaban, edoxaban, apixaban, betrixaban) or heparin; patients receiving thrombolysis; patients with coagulation disorders.
- •Pregnant or lactating women.
- •Patients deemed unsuitable for use by clinicians apart from the exclusion criteria listed above.
- •Patients with severe allergies to lecanemab or any excipients of this product.
结局指标
主要结局
Chang of CDR-SB score
时间窗: baseline, 9 month, 18 month
CDR-SB, clinical dementia rating-sum of boxes
次要结局
- Change of ADAS-cog score(baseline, 9 month, 18 month)
- Change of amyloid burden(baseline, 9 month, 18 month)
- Change of ADCS-ADL score(baseline, 9 month, 18 month)
- Change of MoCA score(baseline, 9 month, 18 month)
- Change of BNT score(baseline, 9 month, 18 month)
- Change of TMT score(baseline, 9 month, 18 month)
- Change of HAMA and HAMD score(baseline, 9 month, 18 month)
- Change of biomarkers(baseline, 9 month, 18 month)
- Positron emission tomography (PET)(baseline, 9 month, 18 month)
- Change of structural MRI(baseline, 9 month, 18 month)
- Change of functional MRI(baseline, 9 month, 18 month)
- Change of magnetic susceptibility(baseline, 9 month, 18 month)
- Change of perfusion imaging(baseline, 9 month, 18 month)
- Whole Genome Sequencing(baseline)
- Change of speech information(baseline, 9 month, 18 month)
研究者
研究点 (15)
Loading locations...
相似试验
进行中（未招募）
不适用
Effects of a combination treatment with lercanidipine + enalapril vs. lercanidipine + hydrochlorothiazide on blood pressure and endothelial function in essential hypertensive patients - enalercaprimary hypertensionMedDRA version: 9.1Level: HLGTClassification code 10057166EUCTR2010-022232-37-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
招募中
不适用
Real-World Evidence Study on AbeMaciclib Treatment Patterns and Effectiveness in Patients with HR+/HER2- Locally Advanced or Metastatic BReAst CancEr in Kuwait and Lebanon.locally advanced or metastatic breast cancerT51.2Breast CancerLBCTR2022035014Eli Lilly100
进行中（未招募）
不适用
Phase I/II Trial of Lenalidomide in Combination with Vorinostat and Dexamethasone as Therapy in Relapsed or Refractory Patients with Peripheral T-Cell Non-Hodgkin’s Lymphoma (PTCL)EUCTR2008-006919-20-ATArbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH
进行中（未招募）
不适用
A Phase I/II Study of Lenalidomide in Patients with Chronic Myelomonocytic LeukemiaEUCTR2009-017147-33-ATAGMT gemeinnützige GmbH
招募中
1 期
A Trial to Learn if Linvoseltamab is Safe and Works in Adults with Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)Relapsed or Refractory Systemic Light Chain AmyloidosisMedDRA version: 24.1Level: LLTClassification code: 10086183Term: AL amyloidosis Class: 100000004848CTIS2023-507809-34-00Regeneron Pharmaceuticals Inc.136